Trade Sage Therapeutics, Inc. - SAGE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.20 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 10.36 |
| Open | 10.55 |
| 1-Year Change | -74.67% |
| Day's Range | 10.49 - 10.89 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 10.40 | 0.68 | 7.00% | 9.72 | 10.61 | 9.63 |
| Jul 24, 2024 | 10.33 | 0.42 | 4.24% | 9.91 | 11.02 | 9.91 |
| Jul 23, 2024 | 13.02 | 0.60 | 4.83% | 12.42 | 13.42 | 12.24 |
| Jul 22, 2024 | 12.75 | 0.46 | 3.74% | 12.29 | 12.77 | 12.17 |
| Jul 19, 2024 | 12.26 | 0.29 | 2.42% | 11.97 | 12.49 | 11.93 |
| Jul 18, 2024 | 12.14 | 0.25 | 2.10% | 11.89 | 12.20 | 11.59 |
| Jul 17, 2024 | 12.12 | 0.18 | 1.51% | 11.94 | 12.60 | 11.74 |
| Jul 16, 2024 | 12.06 | 0.23 | 1.94% | 11.83 | 12.23 | 11.83 |
| Jul 15, 2024 | 11.70 | 0.08 | 0.69% | 11.62 | 11.90 | 11.46 |
| Jul 12, 2024 | 11.71 | 0.03 | 0.26% | 11.68 | 11.90 | 11.46 |
| Jul 11, 2024 | 11.68 | 0.44 | 3.91% | 11.24 | 12.01 | 11.16 |
| Jul 10, 2024 | 10.98 | -0.40 | -3.51% | 11.38 | 11.50 | 10.79 |
| Jul 9, 2024 | 11.42 | 0.61 | 5.64% | 10.81 | 11.58 | 10.71 |
| Jul 8, 2024 | 10.90 | 0.05 | 0.46% | 10.85 | 11.07 | 10.35 |
| Jul 5, 2024 | 10.72 | 0.24 | 2.29% | 10.48 | 10.93 | 10.30 |
| Jul 3, 2024 | 10.53 | -0.29 | -2.68% | 10.82 | 10.92 | 10.53 |
| Jul 2, 2024 | 10.77 | 0.08 | 0.75% | 10.69 | 10.96 | 10.55 |
| Jul 1, 2024 | 10.99 | 0.24 | 2.23% | 10.75 | 11.20 | 10.58 |
| Jun 28, 2024 | 10.77 | 0.20 | 1.89% | 10.57 | 10.84 | 10.49 |
| Jun 27, 2024 | 10.65 | -0.13 | -1.21% | 10.78 | 10.83 | 10.51 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Sage Therapeutic Company profile
About SAGE Therapeutics Inc
SAGE Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD), in adults. The Company's products also include ZULRESSO (Brexanolone) CIV Injection, Zuranolone (SAGE-217), SAGE-324 and SAGE-718. Its next advanced product candidate is SAGE-217, is an oral compound that is in Phase III clinical development in PPD and depressive disorder (MDD). Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing and conducting a placebo-controlled Phase II clinical trial evaluating the safety and efficacy of SAGE-324 in the treatment of essential tremor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, SAGE Therapeutics Inc revenues decreased 99% to $6.3M. Net loss totaled $457.9M vs. income of $606.1M. Revenues reflect Collaboration revenue decrease from $1.11B to $0K, Product decrease of 6% to $6.3M. Net loss reflects Stock-based Compensation in R&D increase of 17% to $49.7M (expense), Stock-based Compensation in SGA increase of 6% to $54.9M (expense), Other income (expense).
Equity composition
Common Stock, $0.0001 Par, 07/14, auth. 120M shares,. 24,961,926 issd,. Insiders owns approx. 20.03%.
| Industry: | Bio Therapeutic Drugs |
215 1st St
CAMBRIDGE
MASSACHUSETTS 02142
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com